Publications by authors named "Steven A Johnson"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

2,216

Total Likes

83

Extended Reach

235,096

Social Features

26
C
Comparison of State-Level Regulations for Cannabis Contaminants and Implications for Public Health.
Laura E Jameson, Kendra D Conrow, Dorina V Pinkhasova, Haleigh L Boulanger, Hyunji Ha, Negar Jourabchian, Steven A Johnson, Michael P Simeone, Iniobong A Afia, Thomas M Cahill

Environ Health Perspect· September 2022

Videos about Article: user user

2 2 24 4 137 2

View All Article and Social Media Activity
F
Field experiments on the effects of fire on parasite transmission to amphibian hosts.
Nicole Ortega, Alexander Shepack, Wayne Price, Todd Campbell, Kym Rouse Holzwart, Steven A Johnson

Ecology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.
Per Svenningsson, Per Odin, Filip Bergquist, Karin Wirdefeldt, Dag Nyholm, Steven A Johnson

Mov Disord· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Lisdexamfetamine in Preschool Children With Attention-Deficit/Hyperactivity Disorder.
Ann C Childress, Eric Lloyd, Leslie Jacobsen, Lhanoo Gunawardhana, Steven A Johnson

J Am Acad Child Adolesc Psychiatry· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4-5 Years with Attention-Deficit/Hyperactivity Disorder.
Ann C Childress, Eric Lloyd, Steven A Johnson, Lhanoo Gunawardhana, Valerie Arnold

J Child Adolesc Psychopharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating Sex and Gender-based Medical Education Into Residency Curricula.
Alyson J McGregor, Marna Rayl Greenberg, Rebecca Barron, Lauren A Walter, Jeannette Wolfe, Steven A Johnson

AEM Educ Train· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Chikungunya virus: An emerging US pathogen.
Thomas M Nappe, Craig M Chuhran, Steven A Johnson

World J Emerg Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pediatric stroke presenting as a seizure.
Katie L Ahmadzadeh, Vartika Bhardwaj, Steven A Johnson, Kathleen E Kane

Case Rep Emerg Med· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzobistriazinones and related heterocyclic ring systems as potent, orally bioavailable positive allosteric AMPA receptor modulators.
Rudolf Mueller, Stanislaw Rachwal, Mark A Varney, Steven A Johnson, Kashinatham Alisala

Bioorg Med Chem Lett· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phlegmonous gastritis and group A streptococcal toxic shock syndrome in a patient following functional endoscopic sinus surgery.
David C Paik, James D Larson, Steven A Johnson, Katherine Sahm, Ehyal Shweiki

Surg Infect (Larchmt)· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.
Donald C Goff, J Steven Lamberti, Andrew C Leon, Michael F Green, Alexander L Miller, Steven A Johnson

Neuropsychopharmacology· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial.
Elizabeth Berry-Kravis, Sue Ellen Krause, Sandra S Block, Steve Guter, Joanne Wuu, Steven A Johnson

J Child Adolesc Psychopharmacol· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report.
Steven A Johnson, Vincent F Simmon

J Mol Neurosci· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis